摘要
目的 评价植入式静脉输液港在乳腺癌化疗患者中的应用价值。方法 选取我病区自2012年5月～2015年7月收治的乳腺癌化疗患者436例,分别经静脉输液港（IVAP组,n=356）和常规中心静脉置管（CVC组,n=80）行输液化疗,采用χ2检验或Fisher精确检验比较两组患者留管期间生活质量评分优良率及并发症发生率。结果与CVC组比较,IVAP组患者有更高的生活质量评分优良率（94.9%vs 85.0%,χ2=10.081,P=0.002）和更低的非计划拔管、血栓形成率、穿刺处感染、导管相关血液感染、导管断裂/移位、导管功能障碍发生率（分别为2.25%vs8.75%,P=0.004;7.87%vs 15.00%,P=0.046;1.40%vs 6.25%,P=0.009;0.56%vs 3.75%,P=0.045;0%vs 2.50%,P=0.033;0.28%vs 5.00%,P=0.005）,差异具有统计学意义。结论 使用植入式静脉输液港的主要并发症为血栓形成,相较于CVC,其明显提高了乳腺癌化疗患者生活质量,减少了并发症的发生,是更为安全、方便、舒适的输液途径。
Objective To evaluate the clinical value of implantable venous-access port （IVAP） in breast cancer pa- tients in intravenous chemotherapy. Methods Totally 436 breast cancer patients who underwent chemotherapy in our department from May 2012 to July 2015 were divided into CVC group （n=80） and IVAP group （n=356）. Complication incidence rates and quality of life during intravenous chemotherapy were compared. Results Compared with CVC group, the quality of life in patients of IVAP group increased significantly（94.9% vs 85.0%, X2=10.081 ,P=0.002）. Incidence rates of unplanned tube drawing,thrombosis,infection at puncture location,catheter-related bloodstream infection, catheter malfunction,catheter fracture/shift in IVAP group were all lower than those in CVC group （2.25% vs 8.75%, P=0.004; 7.87% vs 15.00% ,P=0.046; 1.40% vs 6.25%,P=0.009; 0.56% vs 3.75%,P=0.045; 0% vs 2.50%,P=0.033; 0.28% vs 5.00%,P=0.005, respectively）. Conclusion The most commom complication of IVAP is thrombosis. Compared with CVC, IVAP brings fewer complications and more comfortable life,which should be a better choice for intravenous chemotherapy in breast cancer patients .
出处
《中国现代医生》
2016年第28期51-53,56,共4页
China Modern Doctor
关键词
植入式静脉输液港
乳腺癌
化疗
并发症
Implantable venous-access port
Breast cancer
Chemotherapy
Complication
